person · Reporting owner
Starling William N JR
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ASENSUS SURGICAL, INC.
Report date August 22, 2024 · Filed August 22, 2024
Section 16 reporting ended · disclosed 2024-08-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-08-22 transaction · row 1
1 source rowRow 1 · 2024-08-22 · Disposition to issuer · Disposed 13,846 · Balance 0 F1: The reported securities were disposed of pursuant to the terms of an Agreement and Plan of Merger (the "Merger Agreement")dated as of June 6, 2024, by and among Asensus Surgical, Inc., a Delaware corporation ("Asensus"), KARL STORZ Endoscopy-America, Inc., a California corporation ("Parent"), and Karl Storz California Inc., a California corporation ("Merger Sub"), pursuant to which Merger Sub merged with and into Asensus with Asensus as the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger, the reporting person received $0.35 in cash, without interest and less applicable withholding taxes for each share of common stock. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2024-08-22 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-08-22 · Disposition to issuer · Disposed 39,134 · Balance 0 F1: The reported securities were disposed of pursuant to the terms of an Agreement and Plan of Merger (the "Merger Agreement")dated as of June 6, 2024, by and among Asensus Surgical, Inc., a Delaware corporation ("Asensus"), KARL STORZ Endoscopy-America, Inc., a California corporation ("Parent"), and Karl Storz California Inc., a California corporation ("Merger Sub"), pursuant to which Merger Sub merged with and into Asensus with Asensus as the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger, the reporting person received $0.35 in cash, without interest and less applicable withholding taxes for each share of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the terms of an Agreement and Plan of Merger (the "Merger Agreement")dated as of June 6, 2024, by and among Asensus Surgical, Inc., a Delaware corporation ("Asensus"), KARL STORZ Endoscopy-America, Inc., a California corporation ("Parent"), and Karl Storz California Inc., a California corporation ("Merger Sub"), pursuant to which Merger Sub merged with and into Asensus with Asensus as the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger, the reporting person received $0.35 in cash, without interest and less applicable withholding taxes for each share of common stock.
Inspire Medical Systems, Inc.
Report date May 07, 2018 · Filed May 10, 2018
Jointly reported with SYNERGY LIFE SCIENCE PARTNERS L P, Synergy Venture Partners, LLC, Stack Richard S.
Section 16 reporting ended · disclosed 2018-05-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,095,507 |
Last balance in matching sequence
After 2018-05-07 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2018-05-07 · Conversion · Acquired 741,494 · Balance 741,494 F1: Shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1855 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F4: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. Row 2 · 2018-05-07 · Conversion · Acquired 419,663 · Balance 1,161,157 F2: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. Row 3 · 2018-05-07 · Conversion · Acquired 195,465 · Balance 1,356,622 F2: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. Row 4 · 2018-05-07 · Conversion · Acquired 272,391 · Balance 1,629,013 F3: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. Row 5 · 2018-05-07 · Conversion · Acquired 466,494 · Balance 2,095,507 F2: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-05-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-07 · Conversion · Disposed 3,998,154 · Balance 0 F1: Shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1855 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F4: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-05-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-05-07 · Conversion · Disposed 2,790,760 · Balance 0 F2: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-05-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-05-07 · Conversion · Disposed 1,299,847 · Balance 0 F2: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. |
| Series E Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-05-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-05-07 · Conversion · Disposed 1,576,336 · Balance 0 F3: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. |
| Series F Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-05-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-05-07 · Conversion · Disposed 3,102,190 · Balance 0 F2: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1855 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date.
F2: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date.
F3: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date.
F4: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein.
iRhythm Holdings, Inc.
Report date June 07, 2017 · Filed June 09, 2017
Jointly reported with SYNERGY LIFE SCIENCE PARTNERS L P, Synergy Venture Partners, LLC, Jain Mudit K., Stack Richard S.
Section 16 reporting ended · disclosed 2017-06-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Synergy Life Science Partners, LP | 2,034,524 |
Last balance in matching sequence
After 2017-06-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-06-07 · Sale · Disposed 271,812 · Balance 2,112,712 F1: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $37.00 to $37.58 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Messrs. Stack, Jain and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Each Reporting Person disclaims beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. Row 2 · 2017-06-08 · Sale · Disposed 78,188 · Balance 2,034,524 F3: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $37.65 to $38.54 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Messrs. Stack, Jain and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Each Reporting Person disclaims beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $37.00 to $37.58 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F2: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Messrs. Stack, Jain and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Each Reporting Person disclaims beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein.
F3: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $37.65 to $38.54 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 22, 2024 Filed Aug 22, 2024 09:06 UTC | ASENSUS SURGICAL, INC. ASXC · Entity 88098 | Disposition to issuerCommon Stock | 39,134 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-027540 · rdgdoc.xml · nonDerivative · entry 2 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · price: The reported securities were disposed of pursuant to the terms of an Agreement and Plan of Merger (the "Merger Agreement")dated as of June 6, 2024, by and among Asensus Surgical, Inc., a Delaware corporation ("Asensus"), KARL STORZ Endoscopy-America, Inc., a California corporation ("Parent"), and Karl Storz California Inc., a California corporation ("Merger Sub"), pursuant to which Merger Sub merged with and into Asensus with Asensus as the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger, the reporting person received $0.35 in cash, without interest and less applicable withholding taxes for each share of common stock. Read SEC document |
| August 22, 2024 Filed Aug 22, 2024 09:06 UTC | ASENSUS SURGICAL, INC. ASXC · Entity 88098 | Disposition to issuerCommon Stock | 13,846 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-027540 · rdgdoc.xml · nonDerivative · entry 1 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The reported securities were disposed of pursuant to the terms of an Agreement and Plan of Merger (the "Merger Agreement")dated as of June 6, 2024, by and among Asensus Surgical, Inc., a Delaware corporation ("Asensus"), KARL STORZ Endoscopy-America, Inc., a California corporation ("Parent"), and Karl Storz California Inc., a California corporation ("Merger Sub"), pursuant to which Merger Sub merged with and into Asensus with Asensus as the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger, the reporting person received $0.35 in cash, without interest and less applicable withholding taxes for each share of common stock. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 18:26 UTC | ASENSUS SURGICAL, INC. ASXC · Entity 88098 | SaleCommon Stock | 18,134 | $0.28 | $5,077.52 |
DisclosureSEC source: 0001209191-23-059023 · doc4.xml · nonDerivative · entry 2 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Synecor LLC Disclosed balance after: 0 F1 · kind: Synecor LLC, the registered owner of the shares, is dissolving effective December 31, 2023. William Starling, the trustee of the Buyer, is the CEO of Synecor LLC and is an independent director of Asensus Surgical, Inc. A trust of which William Starling is a trustee and settlor bought the shares of Asensus Surgical, Inc. from Synecor LLC for the closing price on the date of purchase. F1 · balance_after: Synecor LLC, the registered owner of the shares, is dissolving effective December 31, 2023. William Starling, the trustee of the Buyer, is the CEO of Synecor LLC and is an independent director of Asensus Surgical, Inc. A trust of which William Starling is a trustee and settlor bought the shares of Asensus Surgical, Inc. from Synecor LLC for the closing price on the date of purchase. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 18:26 UTC | ASENSUS SURGICAL, INC. ASXC · Entity 88098 | PurchaseCommon Stock | 18,134 | $0.28 | $5,077.52 |
DisclosureSEC source: 0001209191-23-059023 · doc4.xml · nonDerivative · entry 1 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 39,134 F1 · kind: Synecor LLC, the registered owner of the shares, is dissolving effective December 31, 2023. William Starling, the trustee of the Buyer, is the CEO of Synecor LLC and is an independent director of Asensus Surgical, Inc. A trust of which William Starling is a trustee and settlor bought the shares of Asensus Surgical, Inc. from Synecor LLC for the closing price on the date of purchase. F1 · balance_after: Synecor LLC, the registered owner of the shares, is dissolving effective December 31, 2023. William Starling, the trustee of the Buyer, is the CEO of Synecor LLC and is an independent director of Asensus Surgical, Inc. A trust of which William Starling is a trustee and settlor bought the shares of Asensus Surgical, Inc. from Synecor LLC for the closing price on the date of purchase. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 17:03 UTC | ASENSUS SURGICAL, INC. ASXC · Entity 88098 | GrantStock Option · Derivative | 55,748 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001209191-23-035495 · doc4.xml · derivative · entry 1 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,748 Underlying: Common Stock · 55,748 shares Expires 2030-06-06 F1 · security: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan. F2 · derivative.exercise_date: The stock options will vest on a quarterly basis over the one year following the date of grant, with the first vesting on the date of grant. Read SEC document |
| June 14, 2022 Filed Jun 15, 2022 19:36 UTC | ASENSUS SURGICAL, INC. ASXC · Entity 88098 | GrantStock Option · Derivative | 55,340 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001209191-22-037126 · doc4.xml · derivative · entry 4 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,340 Underlying: Common Stock · 55,340 shares Expires 2029-06-14 F4 · security: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan. F5 · derivative.exercise_date: The stock options will vest on a quarterly basis over the one year following the date of grant, with the first vesting on the date of grant. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 19:36 UTC | ASENSUS SURGICAL, INC. ASXC · Entity 88098 | SaleCommon Stock | 27,010 | $0.40 | $10,804.00 |
DisclosureSEC source: 0001209191-22-037126 · doc4.xml · nonDerivative · entry 1 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,846 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.4094 to $0.39, with a weighted average price per share of $0.40. The reporting person undertakes to provide to Asensus Surgical, Inc., any security holder of Asensus Surgical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 19:13 UTC | ASENSUS SURGICAL, INC. ASXC · Entity 88098 | GrantCommon Stock | 13,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045186 · doc4.xml · nonDerivative · entry 1 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,856 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Registrant's common stock. F2 · shares: Forfeiture restrictions will lapse on the RSUs on the first anniversary of the date of grant, provided that if the date of the 2022 annual meeting of stockholders is earlier, the restrictions will lapse on the date of the annual meeting. F1 · price: Represents restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Registrant's common stock. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 19:13 UTC | ASENSUS SURGICAL, INC. ASXC · Entity 88098 | GrantStock Option · Derivative | 4,310 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001209191-21-045186 · doc4.xml · derivative · entry 4 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,310 Underlying: Common Stock · 4,310 shares Expires 2028-06-30 F5 · security: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan in lieu of an annual cash retainer, paid quarterly in arrears for the quarter ended June 30, 2021. F6 · derivative.exercise_date: The award is fully exercisable six months after the grant date, subject to earlier acceleration as approved by the Board of Directors. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 18:13 UTC | ASENSUS SURGICAL, INC. ASXC · Entity 88098 | GrantStock Option · Derivative | 3,628 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001209191-21-024775 · doc4.xml · derivative · entry 1 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,628 Underlying: Common Stock · 3,628 shares Expires 2028-03-31 F1 · security: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan in lieu of an annual cash retainer, paid quarterly in arrears for the quarter ended March 31, 2021. F2 · derivative.exercise_date: The award is fully exercisable six months after the grant date, subject to earlier acceleration as approved by the Board of Directors. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 19:12 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantStock Option · Derivative | 14,756 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-21-001612 · doc4.xml · derivative · entry 1 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,756 Underlying: Common Stock · 14,756 shares Expires 2028-12-31 F1 · security: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan in lieu of an annual cash retainer, paid quarterly in arrears for the quarter ended December 31, 2020. F2 · derivative.exercise_date: The award is fully exercisable six months after the grant date, subject to earlier acceleration as approved by the Board of Directors. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 17:42 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantStock Option · Derivative | 14,852 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001209191-20-053300 · doc4.xml · derivative · entry 1 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,852 Underlying: Common Stock · 14,852 shares Expires 2027-09-30 F1 · security: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan in lieu of an annual cash retainer, paid quarterly in arrears for the quarter ended September 30, 2020. F2 · derivative.exercise_date: The award is fully exercisable six months after the grant date, subject to earlier acceleration as approved by the Board of Directors. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:05 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantStock Option · Derivative | 31,250 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-20-035705 · doc4.xml · derivative · entry 5 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2027-06-08 F5 · derivative.exercise_date: The stock options will vest 25% on each of September 8, 2020, December 8, 2020, March 8, 2021 and June 8, 2021, provided that if the date of the 2021 annual meeting of stockholders is earlier, the last vesting occurs on the date of the annual meeting. Subject to acceleration of vesting in full upon consummation of a change in control of the Registrant. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:05 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantCommon Stock | 22,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-035705 · doc4.xml · nonDerivative · entry 2 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,010 F1 · shares: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. F2 · shares: The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the Reporting Person remains in continuous service during the vesting period. F1 · price: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:05 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantCommon Stock | 4,510 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-035705 · doc4.xml · nonDerivative · entry 1 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,510 F1 · shares: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. F2 · shares: The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the Reporting Person remains in continuous service during the vesting period. F1 · price: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. Read SEC document |
| April 13, 2020 Filed Apr 16, 2020 21:23 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | OtherCommon Stock | 9,313 | $0.40 | $3,722.41 |
DisclosureSEC source: 0001209191-20-024698 · doc4.xml · nonDerivative · entry 2 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 21,281 F2 · kind: Reflects a liquidation distribution to the W. Starling and D. Starling, Trustees of the Starling Family Trust, UDT August 15, 1990 (the "Family Trust") of shares of common stock by Synergy Life Science Partners, L.P., a dissolving limited partnership. The reporting person is a trustee of the Family Trust and was a managing director of the dissolving limited partnership. F2 · balance_after: Reflects a liquidation distribution to the W. Starling and D. Starling, Trustees of the Starling Family Trust, UDT August 15, 1990 (the "Family Trust") of shares of common stock by Synergy Life Science Partners, L.P., a dissolving limited partnership. The reporting person is a trustee of the Family Trust and was a managing director of the dissolving limited partnership. Read SEC document |
| April 13, 2020 Filed Apr 16, 2020 21:23 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | OtherCommon Stock | 131,102 | $0.40 | $52,401.47 |
DisclosureSEC source: 0001209191-20-024698 · doc4.xml · nonDerivative · entry 1 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 0 F1 · kind: Distribution of all shares in liquidation by Synergy Life Science Partners L.P. The reporting person was a managing director of Synergy Life Science Partners L.P. F1 · balance_after: Distribution of all shares in liquidation by Synergy Life Science Partners L.P. The reporting person was a managing director of Synergy Life Science Partners L.P. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 19:44 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | SaleCommon Stock | 6,015 | $1.44 | $8,661.60 |
DisclosureSEC source: 0001209191-19-061657 · doc4.xml · nonDerivative · entry 2 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 11,968 F1 · security: Shares of Common Stock sold by W. Starling and D. Starling, Trustees of the Starling Family Trust, UDT August 15, 1990. F3 · price: The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.44 to $1.445 inclusive. The reporting person undertakes to provide to the Registrant, any security holder of the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · balance_after: Reflects a reverse stock split of the Registrant's common stock at a ratio of one-for-thirteen with marketplace effectiveness on December 12, 2019 whereby the resulting fractional share was rounded up to the nearest whole share. F1 · ownership.nature: Shares of Common Stock sold by W. Starling and D. Starling, Trustees of the Starling Family Trust, UDT August 15, 1990. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 19:44 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | SaleCommon Stock | 3,587 | $1.39 | $4,985.93 |
DisclosureSEC source: 0001209191-19-061657 · doc4.xml · nonDerivative · entry 1 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 17,983 F1 · security: Shares of Common Stock sold by W. Starling and D. Starling, Trustees of the Starling Family Trust, UDT August 15, 1990. F2 · balance_after: Reflects a reverse stock split of the Registrant's common stock at a ratio of one-for-thirteen with marketplace effectiveness on December 12, 2019 whereby the resulting fractional share was rounded up to the nearest whole share. F1 · ownership.nature: Shares of Common Stock sold by W. Starling and D. Starling, Trustees of the Starling Family Trust, UDT August 15, 1990. Read SEC document |
| April 25, 2019 Filed Apr 26, 2019 20:09 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantStock Option Award · Derivative | 29,104 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001209191-19-026322 · doc4.xml · derivative · entry 5 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,104 Underlying: Common Stock · 29,104 shares Expires 2029-04-25 F6 · derivative.exercise_date: The vesting schedule is 25% of the stock option award on July 1, 2019, October 1, 2019, January 1, 2020 and April 1, 2020. Subject to acceleration of vesting in full upon consummation of a change in control of the registrant. Read SEC document |
| April 25, 2019 Filed Apr 26, 2019 20:09 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantCommon Stock | 20,380 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-026322 · doc4.xml · nonDerivative · entry 1 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,380 F1 · shares: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. F2 · shares: The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the reporting person remains in continuous service during the vesting period. F1 · price: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. Read SEC document |
| September 27, 2018 Filed Sep 27, 2018 20:01 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | SaleCommon Stock | 1,139,649 | $6.13 | $6,986,048.37 |
DisclosureSEC source: 0001209191-18-052512 · doc4.xml · nonDerivative · entry 3 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,704,320 F1 · security: Synergy Life Science Partners, L.P., the holder of these shares, sold an aggregate of 1,700,000 shares of TransEnterix stock on September 25, 2018, an aggregate of 775,000 shares on September 26, 2018, and an aggregate of 1,139,649 shares on September 27, 2018. The reporting person is a control person of the General Partner of Synergy Life Science Partners, L.P. The reporting person disclaims any beneficial ownership of the shares of TransEnterix stock owned by Synergy Life Science Partners, L.P. and has no pecuniary interest in such shares. F4 · price: The sale price reported in Column 4 is a weighted average price. These shares were sold by Synergy Life Science Partners, L.P. in multiple transactions at prices ranging from $6.05 to $6.205 inclusive. The reporting person undertakes to provide to TransEnterix, Inc., any security holder of TransEnterix, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F1 · balance_after: Synergy Life Science Partners, L.P., the holder of these shares, sold an aggregate of 1,700,000 shares of TransEnterix stock on September 25, 2018, an aggregate of 775,000 shares on September 26, 2018, and an aggregate of 1,139,649 shares on September 27, 2018. The reporting person is a control person of the General Partner of Synergy Life Science Partners, L.P. The reporting person disclaims any beneficial ownership of the shares of TransEnterix stock owned by Synergy Life Science Partners, L.P. and has no pecuniary interest in such shares. F1 · ownership.nature: Synergy Life Science Partners, L.P., the holder of these shares, sold an aggregate of 1,700,000 shares of TransEnterix stock on September 25, 2018, an aggregate of 775,000 shares on September 26, 2018, and an aggregate of 1,139,649 shares on September 27, 2018. The reporting person is a control person of the General Partner of Synergy Life Science Partners, L.P. The reporting person disclaims any beneficial ownership of the shares of TransEnterix stock owned by Synergy Life Science Partners, L.P. and has no pecuniary interest in such shares. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 20:01 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | SaleCommon Stock | 775,000 | $6.26 | $4,851,500.00 |
DisclosureSEC source: 0001209191-18-052512 · doc4.xml · nonDerivative · entry 2 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,843,969 F1 · security: Synergy Life Science Partners, L.P., the holder of these shares, sold an aggregate of 1,700,000 shares of TransEnterix stock on September 25, 2018, an aggregate of 775,000 shares on September 26, 2018, and an aggregate of 1,139,649 shares on September 27, 2018. The reporting person is a control person of the General Partner of Synergy Life Science Partners, L.P. The reporting person disclaims any beneficial ownership of the shares of TransEnterix stock owned by Synergy Life Science Partners, L.P. and has no pecuniary interest in such shares. F3 · price: The sale price reported in Column 4 is a weighted average price. These shares were sold by Synergy Life Science Partners, L.P. in multiple transactions at prices ranging from $6.20 to $6.475 inclusive. The reporting person undertakes to provide to TransEnterix, Inc., any security holder of TransEnterix, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F1 · balance_after: Synergy Life Science Partners, L.P., the holder of these shares, sold an aggregate of 1,700,000 shares of TransEnterix stock on September 25, 2018, an aggregate of 775,000 shares on September 26, 2018, and an aggregate of 1,139,649 shares on September 27, 2018. The reporting person is a control person of the General Partner of Synergy Life Science Partners, L.P. The reporting person disclaims any beneficial ownership of the shares of TransEnterix stock owned by Synergy Life Science Partners, L.P. and has no pecuniary interest in such shares. F1 · ownership.nature: Synergy Life Science Partners, L.P., the holder of these shares, sold an aggregate of 1,700,000 shares of TransEnterix stock on September 25, 2018, an aggregate of 775,000 shares on September 26, 2018, and an aggregate of 1,139,649 shares on September 27, 2018. The reporting person is a control person of the General Partner of Synergy Life Science Partners, L.P. The reporting person disclaims any beneficial ownership of the shares of TransEnterix stock owned by Synergy Life Science Partners, L.P. and has no pecuniary interest in such shares. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 20:01 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | SaleCommon Stock | 1,700,000 | $6.40 | $10,880,000.00 |
DisclosureSEC source: 0001209191-18-052512 · doc4.xml · nonDerivative · entry 1 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,618,969 F1 · security: Synergy Life Science Partners, L.P., the holder of these shares, sold an aggregate of 1,700,000 shares of TransEnterix stock on September 25, 2018, an aggregate of 775,000 shares on September 26, 2018, and an aggregate of 1,139,649 shares on September 27, 2018. The reporting person is a control person of the General Partner of Synergy Life Science Partners, L.P. The reporting person disclaims any beneficial ownership of the shares of TransEnterix stock owned by Synergy Life Science Partners, L.P. and has no pecuniary interest in such shares. F2 · price: The sale price reported in Column 4 is a weighted average price. These shares were sold by Synergy Life Science Partners, L.P. in multiple transactions at prices ranging from $6.25 to $6.90 inclusive. The reporting person undertakes to provide to TransEnterix, Inc., any security holder of TransEnterix, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F1 · balance_after: Synergy Life Science Partners, L.P., the holder of these shares, sold an aggregate of 1,700,000 shares of TransEnterix stock on September 25, 2018, an aggregate of 775,000 shares on September 26, 2018, and an aggregate of 1,139,649 shares on September 27, 2018. The reporting person is a control person of the General Partner of Synergy Life Science Partners, L.P. The reporting person disclaims any beneficial ownership of the shares of TransEnterix stock owned by Synergy Life Science Partners, L.P. and has no pecuniary interest in such shares. F1 · ownership.nature: Synergy Life Science Partners, L.P., the holder of these shares, sold an aggregate of 1,700,000 shares of TransEnterix stock on September 25, 2018, an aggregate of 775,000 shares on September 26, 2018, and an aggregate of 1,139,649 shares on September 27, 2018. The reporting person is a control person of the General Partner of Synergy Life Science Partners, L.P. The reporting person disclaims any beneficial ownership of the shares of TransEnterix stock owned by Synergy Life Science Partners, L.P. and has no pecuniary interest in such shares. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 19:40 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | OtherCommon Stock | 78,192 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-051149 · doc4.xml · nonDerivative · entry 2 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 213,415 F1 · kind: Synecor, LLC distributed an aggregate of 156,384 shares of TransEnterix stock to its officers in satisfaction of guaranteed payments. The reporting person is the chief executive officer of Synecor, LLC. The reporting person received 78,192 of such shares. F1 · price: Synecor, LLC distributed an aggregate of 156,384 shares of TransEnterix stock to its officers in satisfaction of guaranteed payments. The reporting person is the chief executive officer of Synecor, LLC. The reporting person received 78,192 of such shares. F2 · ownership.direct: Shares of Common Stock held by W. Starling and D. Starling, Trustees of the Starling Family Trust, UDT August 15, 1990. F2 · ownership.nature: Shares of Common Stock held by W. Starling and D. Starling, Trustees of the Starling Family Trust, UDT August 15, 1990. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 19:40 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | OtherCommon Stock | 156,384 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-051149 · doc4.xml · nonDerivative · entry 1 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 235,738 F1 · kind: Synecor, LLC distributed an aggregate of 156,384 shares of TransEnterix stock to its officers in satisfaction of guaranteed payments. The reporting person is the chief executive officer of Synecor, LLC. The reporting person received 78,192 of such shares. F1 · price: Synecor, LLC distributed an aggregate of 156,384 shares of TransEnterix stock to its officers in satisfaction of guaranteed payments. The reporting person is the chief executive officer of Synecor, LLC. The reporting person received 78,192 of such shares. F1 · balance_after: Synecor, LLC distributed an aggregate of 156,384 shares of TransEnterix stock to its officers in satisfaction of guaranteed payments. The reporting person is the chief executive officer of Synecor, LLC. The reporting person received 78,192 of such shares. F1 · ownership.direct: Synecor, LLC distributed an aggregate of 156,384 shares of TransEnterix stock to its officers in satisfaction of guaranteed payments. The reporting person is the chief executive officer of Synecor, LLC. The reporting person received 78,192 of such shares. F1 · ownership.nature: Synecor, LLC distributed an aggregate of 156,384 shares of TransEnterix stock to its officers in satisfaction of guaranteed payments. The reporting person is the chief executive officer of Synecor, LLC. The reporting person received 78,192 of such shares. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 09:00 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | Exercise / conversionStock Option · Derivative | 21,625 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001209191-18-044132 · doc4.xml · derivative · entry 7 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,625 shares Expires 2022-04-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Previously vested. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 09:00 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001209191-18-044132 · doc4.xml · derivative · entry 6 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2027-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Previously vested. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 09:00 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | Exercise / conversionCommon Stock | 21,625 | $0.35 | $7,568.75 |
DisclosureSEC source: 0001209191-18-044132 · doc4.xml · nonDerivative · entry 2 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 09:00 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | Exercise / conversionCommon Stock | 25,000 | $0.48 | $12,000.00 |
DisclosureSEC source: 0001209191-18-044132 · doc4.xml · nonDerivative · entry 1 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2018 Filed May 29, 2018 07:08 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantStock Option Award · Derivative | 35,592 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001209191-18-033661 · doc4.xml · derivative · entry 5 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,592 Underlying: Common Stock · 35,592 shares Expires 2028-05-24 F6 · derivative.exercise_date: The vesting schedule is 25% of the stock option award on each of July 1, 2018, October 1, 2018, January 1, 2019 and April 1, 2019. Read SEC document |
| May 24, 2018 Filed May 29, 2018 07:08 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantCommon Stock | 20,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-033661 · doc4.xml · nonDerivative · entry 1 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,362 F1 · security: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. F1 · price: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. F2 · price: The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the reporting person remains in continuous service during the vesting period. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:22 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionSeries F Convertible Preferred Stock · Derivative | 3,102,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031870 · a4.xml · derivative · entry 10 SYNERGY LIFE SCIENCE PARTNERS L P · CIK 0001384771 · 10% owner Synergy Venture Partners, LLC · CIK 0001584405 · 10% owner Stack Richard S. · CIK 0001584403 · 10% owner Starling William N JR · CIK 0001324130 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 466,494 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F2 · derivative.exercise_date: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F2 · derivative.expiration_date: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4 · ownership.direct: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:22 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionSeries E Convertible Preferred Stock · Derivative | 1,576,336 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031870 · a4.xml · derivative · entry 9 SYNERGY LIFE SCIENCE PARTNERS L P · CIK 0001384771 · 10% owner Synergy Venture Partners, LLC · CIK 0001584405 · 10% owner Stack Richard S. · CIK 0001584403 · 10% owner Starling William N JR · CIK 0001324130 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 272,391 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F3 · derivative.exercise_date: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F3 · derivative.expiration_date: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4 · ownership.direct: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:22 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionSeries D Convertible Preferred Stock · Derivative | 1,299,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031870 · a4.xml · derivative · entry 8 SYNERGY LIFE SCIENCE PARTNERS L P · CIK 0001384771 · 10% owner Synergy Venture Partners, LLC · CIK 0001584405 · 10% owner Stack Richard S. · CIK 0001584403 · 10% owner Starling William N JR · CIK 0001324130 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 195,465 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F2 · derivative.exercise_date: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F2 · derivative.expiration_date: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4 · ownership.direct: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:22 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionSeries C Convertible Preferred Stock · Derivative | 2,790,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031870 · a4.xml · derivative · entry 7 SYNERGY LIFE SCIENCE PARTNERS L P · CIK 0001384771 · 10% owner Synergy Venture Partners, LLC · CIK 0001584405 · 10% owner Stack Richard S. · CIK 0001584403 · 10% owner Starling William N JR · CIK 0001324130 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 419,663 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F2 · derivative.exercise_date: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F2 · derivative.expiration_date: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4 · ownership.direct: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:22 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionSeries B Convertible Preferred Stock · Derivative | 3,998,154 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031870 · a4.xml · derivative · entry 6 SYNERGY LIFE SCIENCE PARTNERS L P · CIK 0001384771 · 10% owner Synergy Venture Partners, LLC · CIK 0001584405 · 10% owner Stack Richard S. · CIK 0001584403 · 10% owner Starling William N JR · CIK 0001324130 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 741,494 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1855 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F1 · derivative.exercise_date: Shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1855 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F1 · derivative.expiration_date: Shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1855 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F4 · ownership.direct: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:22 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionCommon Stock | 466,494 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-031870 · a4.xml · nonDerivative · entry 5 SYNERGY LIFE SCIENCE PARTNERS L P · CIK 0001384771 · 10% owner Synergy Venture Partners, LLC · CIK 0001584405 · 10% owner Stack Richard S. · CIK 0001584403 · 10% owner Starling William N JR · CIK 0001324130 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,095,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4 · ownership.direct: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:22 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionCommon Stock | 272,391 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-031870 · a4.xml · nonDerivative · entry 4 SYNERGY LIFE SCIENCE PARTNERS L P · CIK 0001384771 · 10% owner Synergy Venture Partners, LLC · CIK 0001584405 · 10% owner Stack Richard S. · CIK 0001584403 · 10% owner Starling William N JR · CIK 0001324130 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,629,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4 · ownership.direct: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:22 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionCommon Stock | 195,465 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-031870 · a4.xml · nonDerivative · entry 3 SYNERGY LIFE SCIENCE PARTNERS L P · CIK 0001384771 · 10% owner Synergy Venture Partners, LLC · CIK 0001584405 · 10% owner Stack Richard S. · CIK 0001584403 · 10% owner Starling William N JR · CIK 0001324130 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,356,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4 · ownership.direct: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:22 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionCommon Stock | 419,663 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-031870 · a4.xml · nonDerivative · entry 2 SYNERGY LIFE SCIENCE PARTNERS L P · CIK 0001384771 · 10% owner Synergy Venture Partners, LLC · CIK 0001584405 · 10% owner Stack Richard S. · CIK 0001584403 · 10% owner Starling William N JR · CIK 0001324130 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,161,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4 · ownership.direct: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:22 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionCommon Stock | 741,494 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-031870 · a4.xml · nonDerivative · entry 1 SYNERGY LIFE SCIENCE PARTNERS L P · CIK 0001384771 · 10% owner Synergy Venture Partners, LLC · CIK 0001584405 · 10% owner Stack Richard S. · CIK 0001584403 · 10% owner Starling William N JR · CIK 0001324130 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 741,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1855 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F4 · ownership.direct: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Mudit K. Jain, a director of the Issuer, and each of Messrs. Stack and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Such persons and entities disclaim beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 19:06 UTC | iRhythm Holdings, Inc. IRTC · Entity 1499 | SaleCommon Stock | 78,188 | $37.76 | $2,952,214.69 |
DisclosureSEC source: 0001209191-17-039009 · doc4.xml · nonDerivative · entry 2 SYNERGY LIFE SCIENCE PARTNERS L P · CIK 0001384771 · 10% owner Synergy Venture Partners, LLC · CIK 0001584405 · 10% owner Jain Mudit K. · CIK 0001584404 · 10% owner Starling William N JR · CIK 0001324130 · 10% owner Stack Richard S. · CIK 0001584403 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Synergy Life Science Partners, LP Disclosed balance after: 2,034,524 F3 · price: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $37.65 to $38.54 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Messrs. Stack, Jain and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Each Reporting Person disclaims beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 19:06 UTC | iRhythm Holdings, Inc. IRTC · Entity 1499 | SaleCommon Stock | 271,812 | $37.34 | $10,149,949.34 |
DisclosureSEC source: 0001209191-17-039009 · doc4.xml · nonDerivative · entry 1 SYNERGY LIFE SCIENCE PARTNERS L P · CIK 0001384771 · 10% owner Synergy Venture Partners, LLC · CIK 0001584405 · 10% owner Jain Mudit K. · CIK 0001584404 · 10% owner Starling William N JR · CIK 0001324130 · 10% owner Stack Richard S. · CIK 0001584403 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Synergy Life Science Partners, LP Disclosed balance after: 2,112,712 F1 · price: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $37.00 to $37.58 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: Synergy Venture Partners, LLC ("SVP LLC") serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, SVP LLC possesses sole voting and investment control over the securities owned by Synergy, and may be deemed to have indirect beneficial ownership of the securities held by Synergy. SVP LLC, however, owns no securities of the Issuer directly. Messrs. Stack, Jain and Starling are Managers of SVP LLC and share voting and dispositive power over the shares held by Synergy. Each Reporting Person disclaims beneficial ownership of the shares held by Synergy except to the extent of his or its proportionate pecuniary interest therein. Read SEC document |
| May 25, 2017 Filed May 26, 2017 16:21 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantStock Option Award · Derivative | 25,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001209191-17-035817 · doc4.xml · derivative · entry 1 Starling William N JR · CIK 0001324130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-05-25 F1 · derivative.exercise_date: Vests 25% per quarter on each quarterly anniversary of the date of grant with the final vesting on the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.